| 1 | 1 | | 88R3473 BPG-D |
|---|
| 2 | 2 | | By: Hall, Campbell S.C.R. No. 3 |
|---|
| 3 | 3 | | |
|---|
| 4 | 4 | | |
|---|
| 5 | 5 | | CONCURRENT RESOLUTION |
|---|
| 6 | 6 | | WHEREAS, The American Academy of Pediatrics, American |
|---|
| 7 | 7 | | Medical Association, and Children's Hospital Association wrote a |
|---|
| 8 | 8 | | letter to the United States Attorney General on October 3, 2022, |
|---|
| 9 | 9 | | requesting a Department of Justice investigation of organizations, |
|---|
| 10 | 10 | | individuals, and entities that advocate against what they term |
|---|
| 11 | 11 | | "gender-affirming health care"; and |
|---|
| 12 | 12 | | WHEREAS, "Gender-affirming care" is an unconscionable |
|---|
| 13 | 13 | | misnomer for the abhorrent practice of genital mutilation and the |
|---|
| 14 | 14 | | administration of puberty blockers to children who can not even |
|---|
| 15 | 15 | | legally smoke cigarettes; such "care" leads to irreparable harm, |
|---|
| 16 | 16 | | psychological damage, and a lifetime of trauma; and |
|---|
| 17 | 17 | | WHEREAS, The defenders of "gender-affirming" treatment wish |
|---|
| 18 | 18 | | to silence the voices of those who have undergone gender |
|---|
| 19 | 19 | | transitions and are left with immense, debilitating regret; they |
|---|
| 20 | 20 | | ignore that other countries have examined the issue of whether |
|---|
| 21 | 21 | | minors can adequately understand and properly consent to |
|---|
| 22 | 22 | | "gender-affirming care"; in a landmark 2020 High Court decision in |
|---|
| 23 | 23 | | the United Kingdom, the court ruled that the capacity to legally |
|---|
| 24 | 24 | | consent to taking puberty blockers was "highly unlikely" for |
|---|
| 25 | 25 | | 13-year-olds and "doubtful" for 14- and 15-year-olds; |
|---|
| 26 | 26 | | consequently, the use of puberty blockers was suspended for |
|---|
| 27 | 27 | | children under the age of 16; and |
|---|
| 28 | 28 | | WHEREAS, In July 2022, the U.S. Food and Drug Administration |
|---|
| 29 | 29 | | issued a warning regarding gonadotropin-releasing hormone |
|---|
| 30 | 30 | | agonists, commonly known as puberty blockers; the FDA identified a |
|---|
| 31 | 31 | | plausible association between GnRH agonist use and pseudotumor |
|---|
| 32 | 32 | | cerebri, also known as idiopathic intracranial hypertension, which |
|---|
| 33 | 33 | | occurs when pressure inside the skull spontaneously increases; the |
|---|
| 34 | 34 | | condition can cause brain swelling, severe headaches, nausea, |
|---|
| 35 | 35 | | double vision, and even permanent vision loss, according to the |
|---|
| 36 | 36 | | Mayo Clinic; and |
|---|
| 37 | 37 | | WHEREAS, "Gender-affirming care" is a dangerous practice |
|---|
| 38 | 38 | | that destroys lives, and those who would suppress opposition to |
|---|
| 39 | 39 | | such treatment are deserving of the harshest censure; now, |
|---|
| 40 | 40 | | therefore, be it |
|---|
| 41 | 41 | | RESOLVED, That the 88th Legislature of the State of Texas |
|---|
| 42 | 42 | | hereby express support for ending "gender-affirming care" and |
|---|
| 43 | 43 | | condemn the American Academy of Pediatrics, American Medical |
|---|
| 44 | 44 | | Association, and Children's Hospital Association for their attempt |
|---|
| 45 | 45 | | to suppress objections to such treatment. |
|---|